Table 6.
Multivariable analyses of PFS and OS (Model 2)
| Variables | PFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age (years) | 0.379 | 0.975 | ||||
| ≤ 65 | Ref. | Ref. | ||||
| >65 | 1.204 | 0.796–1.824 | 0.993 | 0.640–1.540 | ||
| ECOG PS | 0.487 | 0.483 | ||||
| 0 | Ref. | Ref. | ||||
| 1 | 1.147 | 0.780–1.686 | 1.154 | 0.773–1.724 | ||
| Clinical stage | 0.004** | 0.004** | ||||
| IIIB | Ref. | Ref. | ||||
| IV | 1.752 | 1.190–2.578 | 1.802 | 1.207–2.690 | ||
| First-line response | 0.035* | 0.015* | ||||
| CR/PR | Ref. | Ref. | ||||
| SD/PD | 1.576 | 1.033–2.406 | 1.754 | 1.117–2.753 | ||
| Albumin | 0.097 | |||||
| Decreased | 1.367 | 0.945–1.978 | ||||
| Normal | Ref. | |||||
| LMR_SUV | < 0.001*** | < 0.001*** | ||||
| Score 0 | Ref. | Ref. | ||||
| Score 1 | 2.017 | 1.233–3.300 | 0.005** | 2.177 | 1.273–3.722 | 0.004** |
| Score 2 | 3.421 | 1.903–6.148 | < 0.001*** | 4.573 | 2.441–8.569 | < 0.001*** |
PFS progression-free survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, CR complete response, PR partial response, SD stable disease, PD progressive disease, LMR lymphocyte-monocyte ratio, SUVmax maximum standardized uptake value, HR hazard ratio, CI confidence intervals. *, p < 0.05; **, p < 0.01; ***, p < 0.001